AiViva Biopharma is developing innovative drug delivery systems to address unmet medical needs. Their core technology, JEL, prolongs the therapeutic effects of drugs and enhances their safety profile. AiViva is exploring applications of this technology across various therapeutic areas, including oncology and urology. In oncology, they are developing drug candidates to directly target solid tumors, potentially leading to improved treatment outcomes. Their urology pipeline includes a product for benign prostatic hyperplasia (BPH) designed to offer a less invasive and more effective treatment option compared to existing therapies.

AiViva Biopharma

Founded: 2016
Location: Newport Beach, California
Employee range: 1-50
Clinical stage: Clin1/Clin2
Therapy area: Non-melanoma skin cancer
Drug types: ONC, OPH, GER, URO
Lead product: AIV001-C01
Funding: not disclosed

Drug notes:

About:

Jobs: